Sandoz Group AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1986-01-01
- Employees
- 20K
- Market Cap
- $19B
- Website
- http://www.sandoz.com
Study to Compare Pharmacokinetics of Tacrolimus Prolonged-release (PR) Capsules and Advagraf® PR Capsules in Stable Kidney Transplant Patients.
- First Posted Date
- 2019-06-07
- Last Posted Date
- 2019-09-17
- Lead Sponsor
- Sandoz
- Registration Number
- NCT03978494
- Locations
- 🇩🇪
Sandoz Investigative Site, Kiel, Germany
Study Investigating PK, PD, Efficacy, Safety, and Immunogenicity of Biosimilar Denosumab (GP2411) in Patients With Postmenopausal Osteoporosis
Phase 3
Completed
- Conditions
- Postmenopausal Women With Osteoporosis
- Interventions
- Biological: EU-Prolia (EU-authorized Prolia®)Biological: GP2411
- First Posted Date
- 2019-06-04
- Last Posted Date
- 2023-03-08
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 527
- Registration Number
- NCT03974100
- Locations
- 🇪🇸
Sandoz Investigational Site, Sevilla, Spain
Real-world Study of Anti-TNFa Treatment Regimes of Hyrimoz or Zessly in Patients With Crohn´s Disease
Completed
- Conditions
- Crohn´s Disease
- First Posted Date
- 2019-03-26
- Last Posted Date
- 2021-06-18
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 63
- Registration Number
- NCT03890445
- Locations
- 🇸🇪
Sandoz Investigational Site, Orebro, Sweden
Study of Loteprednol Etabonate in Adults Undergoing Bilateral Cataract Surgery
Phase 1
Completed
- Conditions
- Inflammation Following Ocular Surgery
- Interventions
- Drug: Reference Listed Drug (RLD)
- First Posted Date
- 2018-05-22
- Last Posted Date
- 2019-11-06
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 381
- Registration Number
- NCT03531697
- Locations
- 🇨🇦
Sandoz Investigative Site, Multiple Locations, Canada
A Study Comparing Two Ferric Carboxymaltose Formulations in Patients With Iron Deficiency Anemia
- First Posted Date
- 2018-01-16
- Last Posted Date
- 2019-05-30
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 71
- Registration Number
- NCT03399084
- Locations
- 🇺🇸
Sandoz Investigative Site, Miami, Florida, United States
Clinical Study for Comparative Assessment of Efficacy and Safety of Angal S, Topical Spray and ANTI-ANGIN® FORMULA, Topical Metered Spray in Treatment of Patients With Uncomplicated Acute Infectious and Inflammatory Diseases of the Pharynx, Accompanied by a Sore Throat
Phase 3
Completed
- Conditions
- Sore Throat
- Interventions
- Drug: Angal S, topical spray [Menthol]Drug: ANTI-ANGIN® FORMULA, topical metered spray
- First Posted Date
- 2017-03-29
- Last Posted Date
- 2019-03-21
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 229
- Registration Number
- NCT03095508
- Locations
- 🇷🇺
Sandoz Investigational Site, Stavropol', Russian Federation
A Local Clinical Study for the Comparative Evaluation of Efficacy and Safety of Angal, Lozenges [Menthol] and ANTI-ANGIN® FORMULA, Lozenges, in Treatment of Patients With a Sore Throat
Phase 3
Completed
- Conditions
- Sore Throat
- Interventions
- Drug: Angal, lozenges [menthol],Drug: ANTI-ANGIN® FORMULA
- First Posted Date
- 2017-03-29
- Last Posted Date
- 2019-03-22
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 228
- Registration Number
- NCT03095521
- Locations
- 🇷🇺
Sandoz Investigational Site, Stavropol', Russian Federation
A Study Comparing Two Rifaximin Tablets in Patients With Travelers' Diarrhea.
Phase 3
Terminated
- Conditions
- Travelers' Diarrhea
- Interventions
- First Posted Date
- 2016-09-30
- Last Posted Date
- 2019-03-25
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 28
- Registration Number
- NCT02920242
- Locations
- 🇲🇽
Sandoz Investigative Site, Mexico City, Mexico
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: Adalimumab - US licensed HumiraBiological: Adalimumab - GP2017
- First Posted Date
- 2016-04-20
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 353
- Registration Number
- NCT02744755
- Locations
- 🇺🇸
Joao Nascimento (Private Practice), Bridgeport, Connecticut, United States
🇺🇸Arthritis & Rheumatic Disease Specialties, Aventura, Florida, United States
🇺🇸RASF - Clinical Research Center, Boca Raton, Florida, United States
Comparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid Arthritis
- First Posted Date
- 2015-12-23
- Last Posted Date
- 2018-09-19
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 376
- Registration Number
- NCT02638259
- Locations
- 🇬🇧
Novartis Investigative Site, London, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath